Sangamo Therapeutics

470 articles with Sangamo Therapeutics

• Sangamo Announces Completion Of TxCell Acquisition

  12/3/2018

  Sangamo Therapeutics, Inc. today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.

• Sangamo Therapeutics Reports Third Quarter 2018 Financial Results

  11/8/2018

  Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

• Sangamo Therapeutics Announces Participation At Upcoming November 2018 Investor Conferences

  11/6/2018

  Sangamo Therapeutics, Inc. announced today that management will participate in the following healthcare investor conferences in November.

• Sangamo Therapeutics Announces Third Quarter 2018 Conference Call and Webcast

  11/1/2018

  Sangamo Therapeutics (Nasdaq: SGMO) announced today that the Company will release its third quarter 2018 financial results after the market closes on Thursday, November 8, 2018.

• 

  Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities

  10/22/2018

  The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.
• 

  Focused on Off-The-Shelf CAR-T, Allogene Therapeutics Hits the Nasdaq at $18 per Share

  10/11/2018

  Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.

• Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares

  10/1/2018

  Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy.

• TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc.

  9/20/2018

  TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.

• Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

  9/18/2018

  ​Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board.

• Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences

  8/30/2018

  Sangamo Therapeutics, Inc. announced today that management will host a conference call on September 5th at 9:00 a.m. ET to discuss clinical data from the CHAMPIONS Study.

• 

  SEC Aims Insider Trading Charges at Former Sangamo Therapeutics Executive

  8/24/2018

  The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”

• Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference

  8/10/2018

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that management will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference in New York City. The presentation is scheduled for Tuesday, August 14th at 4:15 p.m. ET.

• Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

  8/8/2018

  Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A

• Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A

  8/8/2018

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A.

• Sangamo Therapeutics Announces Second Quarter 2018 Conference Call and Webcast

  8/2/2018

  Sangamo Therapeutics, Inc. announced that the Company will release its second quarter 2018 financial results after the market closes on Wednesday, August 8, 2018.

• Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

  7/27/2018

  Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment

• Sangamo Therapeutics to Acquire TxCell

  7/23/2018

  The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development

• Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I

  7/23/2018

  Sangamo Therapeutics, Inc. announced treatment of the first patient in the Phase 1/2 clinical trial evaluating SB-318, an investigational in vivo genome editing therapy for patients with mucopolysaccharidosis type I

• 

  TxCell Shares Surge After Sangamo Therapeutics Announces it Will Acquire the French Company

  7/23/2018

  Shares of France’s TxCell S.A. have skyrocketed about 150 percent this morning after Sangamo Therapeutics announced it was acquiring a majority stake in the company for €72 million (about $82 million) in a cash deal.

• Sangamo Therapeutics Announces Technology Leadership Changes

  7/13/2018

  Sangamo Therapeutics, Inc. announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company.